NEW YORK (Reuters Health) - In patients with de novo CD5-positive diffuse large B-cell lymphoma (CD5+DLBCL), there appear to be two major subgroups with different chromosomal abnormalities and different overall survival, Japanese researchers report in the February issue of Genes, Chromosomes and Cancer.
Dr. Ikuo Miura of Akita University School of Medicine and colleagues note that there are contradictory findings on survival in patients with CD5+DLBCL, but evidence suggests that there are at least two subgroups, with one following a more aggressive course and the other a more favorable one.
To investigate further, the researchers performed cytogenic analysis of 23 patients with the disease.
There was a high incidence of chromosomal aberrations affecting 8p21 and 11q13. The major chromosomal breakpoints were seen at 8p21, 11q13 and 3q27.
No patients had abnormalities at both 8p21 and 11q13, and compared with patients with 11q13 changes, those with alterations at 8p21 had disease with more aggressive clinical features. These included advanced stage, elevated serum LDH level and poor performance status. Their survival was also significantly reduced.
The researchers point out that previous conflicting results on prognosis may be explained in part by these previously unidentified subgroups.
Overall, they conclude that “de novo CD5+ DLBCL carrying an 8p21 anomaly may constitute a subgroup of DLBCL that has aggressive clinical features and short survival.”
Source: Genes Chromosomes Cancer 2005;42:149-157. [ Google search on this article ]
MeSH Headings:Cytological Techniques: Genetic Techniques: Health Occupations: Investigative Techniques: Technology: Technology, Industry, and Agriculture: Technology, Medical: Leukemia, B-Cell: Leukemia, B-Cell, Chronic: Allied Health Occupations: Cytogenetic Analysis: Analytical, Diagnostic and Therapeutic Techniques and Equipment: Biological Sciences: Technology, Food and BeveragesCopyright © 2002 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
